FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991146506> ?p ?o ?g. }

• W1991146506 endingPage "747" @default.
• W1991146506 startingPage "737" @default.
• W1991146506 abstract "BackgroundAdherence to therapy is a key requirement underlying achievement of clinical outcomes in randomized controlled drug registration trials. In postmarketing studies, comparison of adherence among therapies can become more complicated when drug dosing and administration schedules differ or when methods used to measure adherence are not consistently applied.ObjectiveThe objective of this exploratory study was to investigate a broad range of utilization and adherence outcomes associated with subcutaneous biologic treatments for rheumatoid arthritis (RA).MethodsAdult patients (aged ≥18 years) exhibiting ≥2 claims with an RA diagnosis (code 714.x), at least 24 months of continuous medical and pharmacy eligibility, and 30-day supplies of adalimumab, etanercept, or golimumab were selected from the Optum Insight Clinformatics database. Adherence and utilization measures were calculated and compared across treatment groups.ResultsA total of 1532 adalimumab, 2099 etanercept, and 261 golimumab patients met inclusion criteria. Compared with both adalimumab and etanercept patients, golimumab patients were significantly more likely to have a medication possession ratio of ≥0.80 (82% vs 71% vs 62%; P < 0.001) and significantly less likely to have ≥4 late medication refills (6.9% vs 17.7% vs 26.1%; P < 0.001 for all). Etanercept patients had significantly greater refill intervals (37.7 vs 34.9 and 35.1 days) and had the lowest proportion of adherent fills (70% vs 77% and 75%) compared with both golimumab and adalimumab patients (P < 0.001 for all). Bivariate effects were reproduced in multivariate models that controlled for treatment duration.ConclusionsA number of statistically significant medication adherence differences were observed among golimumab, adalimumab, and etanercept patients in treatment for RA. Overall, golimumab patients appeared to be the most adherent group. Findings may be partially attributable to golimumab patients’ likely increased disease severity, their prior experience with biologic medication, or golimumab’s once-monthly dosing schedule, which requires fewer administrations than both adalimumab and etanercept." @default.
• W1991146506 created "2016-06-24" @default.
• W1991146506 creator A5033380416 @default.
• W1991146506 creator A5036543899 @default.
• W1991146506 creator A5052712069 @default.
• W1991146506 creator A5064685751 @default.
• W1991146506 creator A5088746767 @default.
• W1991146506 creator A5090162903 @default.
• W1991146506 date "2014-05-01" @default.
• W1991146506 modified "2023-10-18" @default.
• W1991146506 title "Utilization and Adherence Patterns of Subcutaneously Administered Anti–Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients" @default.
• W1991146506 cites W1551539224 @default.
• W1991146506 cites W1963910487 @default.
• W1991146506 cites W1966756501 @default.
• W1991146506 cites W1971077148 @default.
• W1991146506 cites W1979364075 @default.
• W1991146506 cites W1980559697 @default.
• W1991146506 cites W1983081844 @default.
• W1991146506 cites W1989549387 @default.
• W1991146506 cites W2000445173 @default.
• W1991146506 cites W2001015097 @default.
• W1991146506 cites W2004084979 @default.
• W1991146506 cites W2017716530 @default.
• W1991146506 cites W2021153631 @default.
• W1991146506 cites W2042211986 @default.
• W1991146506 cites W2057652027 @default.
• W1991146506 cites W2063001046 @default.
• W1991146506 cites W2079159057 @default.
• W1991146506 cites W2086089919 @default.
• W1991146506 cites W2098767548 @default.
• W1991146506 cites W2102330818 @default.
• W1991146506 cites W2119566328 @default.
• W1991146506 cites W2119729506 @default.
• W1991146506 cites W2122057071 @default.
• W1991146506 cites W2127077956 @default.
• W1991146506 cites W2136950115 @default.
• W1991146506 cites W2139062201 @default.
• W1991146506 cites W2144897340 @default.
• W1991146506 cites W2149553288 @default.
• W1991146506 cites W2158058290 @default.
• W1991146506 cites W2158131108 @default.
• W1991146506 cites W2165073603 @default.
• W1991146506 cites W2167671703 @default.
• W1991146506 cites W2170521635 @default.
• W1991146506 cites W2235318197 @default.
• W1991146506 cites W2334366154 @default.
• W1991146506 doi "https://doi.org/10.1016/j.clinthera.2014.02.019" @default.
• W1991146506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24661783" @default.
• W1991146506 hasPublicationYear "2014" @default.
• W1991146506 type Work @default.
• W1991146506 sameAs 1991146506 @default.
• W1991146506 citedByCount "41" @default.
• W1991146506 countsByYear W19911465062015 @default.
• W1991146506 countsByYear W19911465062016 @default.
• W1991146506 countsByYear W19911465062017 @default.
• W1991146506 countsByYear W19911465062018 @default.
• W1991146506 countsByYear W19911465062019 @default.
• W1991146506 countsByYear W19911465062020 @default.
• W1991146506 countsByYear W19911465062021 @default.
• W1991146506 countsByYear W19911465062022 @default.
• W1991146506 countsByYear W19911465062023 @default.
• W1991146506 crossrefType "journal-article" @default.
• W1991146506 hasAuthorship W1991146506A5033380416 @default.
• W1991146506 hasAuthorship W1991146506A5036543899 @default.
• W1991146506 hasAuthorship W1991146506A5052712069 @default.
• W1991146506 hasAuthorship W1991146506A5064685751 @default.
• W1991146506 hasAuthorship W1991146506A5088746767 @default.
• W1991146506 hasAuthorship W1991146506A5090162903 @default.
• W1991146506 hasBestOaLocation W19911465061 @default.
• W1991146506 hasConcept C126322002 @default.
• W1991146506 hasConcept C17991360 @default.
• W1991146506 hasConcept C1862650 @default.
• W1991146506 hasConcept C2777138892 @default.
• W1991146506 hasConcept C2777226972 @default.
• W1991146506 hasConcept C2777288759 @default.
• W1991146506 hasConcept C2777575956 @default.
• W1991146506 hasConcept C2780132546 @default.
• W1991146506 hasConcept C2781290027 @default.
• W1991146506 hasConcept C71924100 @default.
• W1991146506 hasConceptScore W1991146506C126322002 @default.
• W1991146506 hasConceptScore W1991146506C17991360 @default.
• W1991146506 hasConceptScore W1991146506C1862650 @default.
• W1991146506 hasConceptScore W1991146506C2777138892 @default.
• W1991146506 hasConceptScore W1991146506C2777226972 @default.
• W1991146506 hasConceptScore W1991146506C2777288759 @default.
• W1991146506 hasConceptScore W1991146506C2777575956 @default.
• W1991146506 hasConceptScore W1991146506C2780132546 @default.
• W1991146506 hasConceptScore W1991146506C2781290027 @default.
• W1991146506 hasConceptScore W1991146506C71924100 @default.
• W1991146506 hasIssue "5" @default.
• W1991146506 hasLocation W19911465061 @default.
• W1991146506 hasLocation W19911465062 @default.
• W1991146506 hasOpenAccess W1991146506 @default.
• W1991146506 hasPrimaryLocation W19911465061 @default.
• W1991146506 hasRelatedWork W1491634525 @default.
• W1991146506 hasRelatedWork W1973470095 @default.
• W1991146506 hasRelatedWork W1976481621 @default.
• W1991146506 hasRelatedWork W1993992685 @default.

• next